Technical Analysis for CATB - Catabasis Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
CATB closed up 7.21 percent on Thursday, January 17, 2019, on 4.33 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical CATB trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||Pocket Pivot||Bullish Swing Setup||-2.84%|
|Jan 17||Volume Surge||Other||-2.84%|
|Jan 17||Calm After Storm||Range Contraction||-2.84%|
|Jan 17||Wide Bands||Range Expansion||-2.84%|
|Jan 17||Above Upper BB||Strength||-2.84%|
|Jan 17||Overbought Stochastic||Strength||-2.84%|
|Jan 17||Up 3 Days in a Row||Strength||-2.84%|
|Jan 17||Up 4 Days in a Row||Strength||-2.84%|
|Jan 17||Upper Bollinger Band Touch||Strength||-2.84%|
|Jan 16||Crossed Above 50 DMA||Bullish||4.17%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Catabasis Pharmaceuticals, Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) linker technology platform. Its SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating various biological targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its SMART linkers. Catabasis is also engaged in developing other product candidates for the treatment of lipid disorders. The Company's product development pipeline includes three clinical-stage product candidates, namely, CAT-1004, CAT-2000 series, including CAT-2054 and CAT-2003, and CAT-4001, and various programs in preclinical development.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CATB news...
|52 Week High||23.8|
|52 Week Low||3.6|
|200-Day Moving Average||9.4064|
|50-Day Moving Average||5.7064|
|20-Day Moving Average||4.9635|
|10-Day Moving Average||5.489|
|Average True Range||0.5855|
|Chandelier Exit (Long, 3 ATRs )||5.1435|
|Chandelier Exit (Short, 3 ATRs )||5.3565|
|Upper Bollinger Band||6.3655|
|Lower Bollinger Band||3.5615|
|Percent B (%b)||1.12|
|MACD Signal Line||-0.1434|
|Market Cap||150.4 Million|
|Num Shares||22.5 Million|
|Price-to-Earnings (P/E) Ratio||-3.91|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||7.56|
|Resistance 3 (R3)||7.53||7.22||7.42|
|Resistance 2 (R2)||7.22||7.00||7.23||7.37|
|Resistance 1 (R1)||6.95||6.86||7.09||6.98||7.32|
|Support 1 (S1)||6.37||6.42||6.51||6.40||6.06|
|Support 2 (S2)||6.06||6.28||6.07||6.01|
|Support 3 (S3)||5.79||6.06||5.97|
|Support 4 (S4)||5.82|